Allspring Global Investments Holdings LLC raised its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 17.7% in the 3rd quarter, Holdings Channel reports. The firm owned 5,322 shares of the company’s stock after purchasing an additional 801 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in BridgeBio Pharma were worth $135,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the business. Bfsg LLC raised its holdings in shares of BridgeBio Pharma by 175.6% in the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after acquiring an additional 790 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of BridgeBio Pharma during the second quarter worth about $48,000. CWM LLC grew its stake in shares of BridgeBio Pharma by 132.9% during the third quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after acquiring an additional 1,964 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in shares of BridgeBio Pharma during the first quarter worth about $117,000. Finally, Amalgamated Bank grew its stake in shares of BridgeBio Pharma by 24.7% during the second quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock worth $123,000 after acquiring an additional 962 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.
BridgeBio Pharma Stock Down 1.1 %
Shares of NASDAQ:BBIO opened at $25.20 on Tuesday. The business has a fifty day moving average of $25.98 and a two-hundred day moving average of $26.41. The stock has a market cap of $4.74 billion, a P/E ratio of -9.58 and a beta of 1.09. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $44.32.
Analyst Upgrades and Downgrades
Read Our Latest Analysis on BridgeBio Pharma
Insider Transactions at BridgeBio Pharma
In other news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the completion of the transaction, the insider now directly owns 25,260,971 shares in the company, valued at approximately $650,470,003.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $25.75, for a total transaction of $149,350,000.00. Following the transaction, the insider now owns 25,260,971 shares of the company’s stock, valued at approximately $650,470,003.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Neil Kumar sold 27,389 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $24.69, for a total value of $676,234.41. Following the transaction, the chief executive officer now directly owns 4,897,443 shares in the company, valued at approximately $120,917,867.67. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,831,544 shares of company stock worth $150,128,821. 24.66% of the stock is currently owned by company insiders.
BridgeBio Pharma Profile
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Further Reading
- Five stocks we like better than BridgeBio Pharma
- Short Selling: How to Short a Stock
- Intel: Is Now the Time to Be Brave?Â
- Comparing and Trading High PE Ratio Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- The How And Why of Investing in Oil Stocks
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report).
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.